Agenus
ProfileJobs

Agenus

Suggest Edit
    • Healthbiotechclinical researchdrug developmentoncologypharmaplatformtherapy

    Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

    Revenue(FY, 2017)
    $42.9 M
    Market capitalization(2018-06-14)
    $291.2 M
    Type
    Public
    HQ
    Lexington, US
    Founded
    1994
    Size (employees)
    255 (est)
    Website
    agenusbio.com
    Agenus was founded in 1994 and is headquartered in Lexington, US
    Report incorrect company information

    Key People/Management at Agenus

    Garo Armen

    Garo Armen

    PhD, Chairman and CEO
    Jennifer Buell

    Jennifer Buell

    PhD, Chief Communications and External Affairs Officer
    Ozer Baysal

    Ozer Baysal

    Chief Commercial Officer and Head of Human Resources
    Michael Plater

    Michael Plater

    PhD, Chief Business Officer
    Alex Duncan

    Alex Duncan

    PhD, Chief Technology Officer and Head of Research
    Christian Cortis

    Christian Cortis

    PhD, Chief Strategy Officer
    Show more

    Agenus Office Locations

    Agenus has offices in Cambridge, Berkeley, New York and Lexington
    Lexington, US (HQ)
    3 Forbes Road
    Berkeley, US
    793 Heinz Ave
    New York, US
    149 Fifth Ave. Suite 500
    Cambridge, GB
    315 Science Park Milton Road
    Show all (4)
    Report incorrect company information

    Agenus Financials and Metrics

    Agenus Financials

    Agenus's revenue was reported to be $42.88 m in FY, 2017
    USD

    Revenue (Q1, 2018)

    		1.6 m

    Net income (Q1, 2018)

    		(54.3 m)

    EBIT (Q1, 2018)

    		(41.7 m)

    Market capitalization (14-Jun-2018)

    		291.2 m

    Closing share price (14-Jun-2018)

    		2.8

    Cash (31-Mar-2018)

    		52.3 m

    EV

    		251.8 m
    Agenus's current market capitalization is $291.2 m.
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		3 m7 m24.8 m22.6 m42.9 m

    Revenue growth, %

    		129%256%(9%)

    General and administrative expense

    		33.7 m

    R&D expense

    		42.7 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		736 k720.9 k3.1 m1.6 m4 m6.4 m6.8 m6 m6.6 m4.4 m27 m4.2 m1.6 m

    General and administrative expense

    		3.6 m5.2 m5.8 m4.9 m5.5 m8 m6.4 m9.2 m7.1 m8.1 m7.8 m8.1 m8.9 m

    R&D expense

    		3.9 m4.5 m5.2 m5.3 m9.2 m24.8 m18.5 m5.8 m6.6 m4.4 m27 m4.2 m29.4 m

    Operating expense total

    		7.5 m9.6 m11.1 m10.2 m14.7 m32.8 m24.9 m15 m13.7 m12.6 m34.7 m12.3 m38.4 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		27.4 m25.7 m136.7 m71.4 m60.2 m

    Accounts Receivable

    		1.2 k9.8 m11.4 m1.1 m

    Inventories

    		95.7 k88.2 k88.2 k79.5 k

    Current Assets

    		28.2 m42.7 m184.1 m91.3 m73.6 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Cash

    		30.2 m73.5 m48.3 m38.4 m79.3 m124.7 m184.1 m78.3 m73.4 m75.4 m113.9 m81.8 m52.3 m

    Accounts Receivable

    		1.1 k2.5 m4.1 m7.3 m10.2 m9.4 m10.3 m6.8 m3.9 m1.1 m

    Inventories

    		3.3 k95.7 k95.7 k88.2 k88.2 k88.2 k88.2 k88.2 k88.2 k87.5 k87 k62.2 k

    Current Assets

    		30.9 m75.3 m67 m55.2 m85.2 m146.3 m208.9 m161.6 m136.1 m109.5 m138 m110.7 m65.2 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(30.1 m)(42.5 m)(87.9 m)(127 m)(120.7 m)

    Depreciation and Amortization

    		586.3 k1.6 m2 m4.9 m6 m

    Inventories

    		16 k(95.7 k)7.5 k7.5 k8.7 k

    Accounts Payable

    		189.6 k(45.9 k)2.7 m419.7 k1.6 m
    Quarterly
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

    Net Income

    		(24.3 m)(357.5 k)(8.4 m)(16.5 m)(18.7 m)(59.2 m)(13.1 m)(31.8 m)(28.3 m)(40.8 m)(17.1 m)(54.3 m)

    Depreciation and Amortization

    		448.2 k266.5 k589.4 k1 m445.5 k885.5 k1.6 m

    Inventories

    		12.7 k(95.7 k)(95.7 k)7.5 k7.5 k88.2 k88.2 k88.2 k88.2 k87.5 k17.3 k

    Accounts Payable

    		(269.4 k)184 k(562.1 k)35.2 k2.3 m797.8 k3.1 m2.5 m5 m3.3 m4.8 m(2.8 m)
    show all
    USDY, 2018

    EV/EBIT

    		-6 x

    EV/CFO

    		-6.3 x

    Financial Leverage

    		-1.2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    Lava Therapeutics
    Health - Private
    Tetherex
    Health - Private
    Regeneron Pharmaceuticals
    Health - Public
    Anavex
    Health - Public
    Compare competitors

    Agenus Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Agenus News and Updates

    May 18, 2018

    Agenus: Buy, Sell Or Hold?

    May 07, 2018

    Agenus' (AGEN) CEO Garo Armen on Q1 2018 Results - Earnings Call Transcript

    April 04, 2018

    Agenus (AGEN) Presents At Jefferies IO Cell Therapy Investment Conference - Slideshow

    March 22, 2018

    Vaccine Adjuvants Market 2018-2023 Trend | Whooping Growth of 10.1% with CSL Ltd, Agenus Inc, Invivogen, Avanti Polar Lipids Inc

    Vaccine Adjuvants Market Information: By Type (Pathogen Components, Particulate Adjuvants, others), By Route of Administration (Oral, Intramuscular, Subcutaneous, and Intradermal), and By End Users (Pediatric, Adult) - Global Forecast Till 2023 Posted via Industry Today. Follow us on Twitter @Indust…
    January 17, 2018

    Research Focused on the Vaccine Adjuvants Market Forecast up to 2025

    Vaccines adjuvants market is expected to be driven by increasing prevalence of conditions such as, allergy, HIV and cancer. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information
    Download PDF